OFATUMUMAB for Secondary progressive multiple sclerosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 1,099 adverse event reports in the FDA FAERS database where OFATUMUMAB was used for Secondary progressive multiple sclerosis.
Most Reported Side Effects for OFATUMUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 5,202 | 17.4% | 8 | 361 |
| Headache | 4,430 | 14.8% | 6 | 300 |
| Pain | 3,382 | 11.3% | 2 | 243 |
| Chills | 3,372 | 11.3% | 2 | 176 |
| Pyrexia | 3,370 | 11.3% | 31 | 436 |
| Influenza like illness | 2,727 | 9.1% | 2 | 149 |
| Nausea | 1,688 | 5.6% | 6 | 160 |
| Multiple sclerosis relapse | 1,525 | 5.1% | 2 | 361 |
| Covid-19 | 1,435 | 4.8% | 12 | 254 |
| Asthenia | 1,393 | 4.7% | 9 | 198 |
| Gait disturbance | 1,342 | 4.5% | 2 | 201 |
| Hypoaesthesia | 1,316 | 4.4% | 0 | 167 |
| Feeling abnormal | 1,306 | 4.4% | 2 | 112 |
| Multiple sclerosis | 1,267 | 4.2% | 6 | 131 |
| Malaise | 1,243 | 4.2% | 10 | 171 |
Other Indications for OFATUMUMAB
Multiple sclerosis (11,816)
Product used for unknown indication (9,779)
Relapsing-remitting multiple sclerosis (3,864)
Relapsing multiple sclerosis (3,705)
Chronic lymphocytic leukaemia (1,216)
Clinically isolated syndrome (1,075)
Multiple sclerosis relapse (158)
Mantle cell lymphoma (143)
Marginal zone lymphoma (131)
Central nervous system lymphoma (128)
Other Drugs Used for Secondary progressive multiple sclerosis
SIPONIMOD (2,265)
OCRELIZUMAB (1,273)
FINGOLIMOD (351)
INTERFERON BETA-1B (146)
RITUXIMAB (131)
NATALIZUMAB (115)
DIMETHYL (96)
INTERFERON BETA-1A (89)
RABEPRAZOLE (86)
DALFAMPRIDINE (85)